Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | CDC25A | P30304 | 2/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.43 |
| ▸ | FNTA | P49354 | 7/20 | 0.39 |
| ▸ | FNTB | P49356 | 7/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5259057 | 0.90 | KDM4E (0.38) | PTPN1CDC25ADUSP3FNTAFNTB | |
| SCHEMBL5259688 | 0.87 | PTPN1 (0.44) | PTPN1CDC25ADUSP3FNTAFNTB | |
| SCHEMBL18333468 | 0.86 | PTPN1 (0.34) | PTPN1CDC25ADUSP3FNTAFNTB | |
| SCHEMBL5259114 | 0.82 | PTPN1 (0.41) | PTPN1CDC25ADUSP3FNTAFNTB | |
| SCHEMBL5259574 | 0.82 | HTR2A (0.41) | NOTUM | |
| SCHEMBL5310989 | 0.81 | PTPN1 (0.44) | PTPN1CDC25ADUSP3FNTAFNTB | |
| SCHEMBL5959279 | 0.80 | MEN1 (0.40) | PTPN1CDC25ADUSP3FNTAFNTB | |
| SCHEMBL5959233 | 0.78 | PTPN1 (0.42) | PTPN1CDC25ADUSP3FNTAFNTB | |
| SCHEMBL5959251 | 0.77 | FNTA (0.44) | PTPN1CDC25ADUSP3FNTAFNTB | |
| SCHEMBL5309804 | 0.76 | PTPN1 (0.42) | PTPN1CDC25ADUSP3FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135480-B2 | Anticarcinogenic agents; colon, lymphoma, lung, prostate and breast cancers | CYTOVIA, INC. (US) | 2006-11-14 | — | — | US | claimed |
| US-20050014759-A1 | Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis | CYTOVIA, INC. | 2005-01-20 | — | — | US | claimed |
| EP-1578424-A4 | SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO 1,2-A| QUINOLINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2007-08-08 | — | — | EP | disclosed |
| US-7135480-B2 | Anticarcinogenic agents; colon, lymphoma, lung, prostate and breast cancers | CYTOVIA, INC. (US) | 2006-11-14 | — | — | US | disclosed |
| EP-1578424-A2 | SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO 1,2-A] QUINOLINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Cytovia, Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050014759-A1 | Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis | CYTOVIA, INC. | 2005-01-20 | — | — | US | disclosed |
| WO-2004055163-A2 | SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO[1,2-A]QUINOLINES | CYTOVIA, INC. (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014759-A1 | Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis | CASP3, CASP7, CASP1 | PTPN1 578/4885CDC25A 31/4885DUSP3 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.